Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;15(8):2589-2610.
doi: 10.1038/s41596-020-0345-1. Epub 2020 Jul 17.

Large-scale site-specific mapping of the O-GalNAc glycoproteome

Affiliations

Large-scale site-specific mapping of the O-GalNAc glycoproteome

Weiming Yang et al. Nat Protoc. 2020 Aug.

Abstract

Protein glycosylation is one of the most common protein modifications. A major type of protein glycosylation is O-GalNAcylation, in which GalNAc-type glycans are attached to protein Ser or Thr residues via an O-linked glycosidic bond. O-GalNAcylation is thought to play roles in protein folding, stability, trafficking and protein interactions, and identification of the site-specific O-GalNAc glycoproteome is a crucial step toward understanding the biological significance of the modification. However, lack of suitable methodology, absence of consensus sequon of O-GalNAcylation sites and complex O-GalNAc glycan structures pose analytical challenges. We recently developed a mass spectrometry-based method called extraction of O-linked glycopeptides (EXoO) that enables large-scale mapping of site-specific mucin-type O-GalNAcylation sites. Here we provide a detailed protocol for EXoO, which includes seven stages of: (1) extraction and proteolytic digestion of proteins to peptides, (2) sequential guanidination and de-salting of peptides, (3) enrichment of glycopeptides, (4) solid-phase peptide conjugation and release of O-GalNAc glycopeptides using the OpeRATOR protease, (5) liquid chromatography with tandem mass spectrometry analysis of O-GalNAc glycopeptides, (6) identification of O-GalNAc glycopeptides by database search and (7) quantification of O-GalNAc glycopeptides. Using this protocol, thousands of O-GalNAcylation sites from hundreds of glycoproteins with information regarding site-specific O-GalNAc glycan can be identified and quantified from complex samples. The protocol can be performed by a researcher with basic proteomics skills and takes about 4 d to complete.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Figures

Figure 1 |
Figure 1 |
Workflow diagram of EXoO protocol and O-GalNAcylation pathway for Gal(1)GalNAc(1)Sia(2). (a) Schematic representation of EXoO method. Image is adapted and from ref.16. (b) Steps of EXoO protocol. (c) O-GalNacylation pathway for Gal(1)GalNAc(1)Sia(2).
Figure 2 |
Figure 2 |
MS/MS spectra of site-specific O-GalNAc glycopeptides. The glycopeptides are generated using the protocol. O-GalNAc glycosylation sites are at the N-termini of peptide sequences. Different glycan compositions are showed to illustrate the approach for defining site-specific O-GalNAc glycans. (a) MS/MS spectra of a glycopeptide with Hex(1)HexNAc(1). (b) MS/MS spectra of a short glycopeptide with a HexNAc. (c) MS/MS spectra of a long glycopeptide with Hex(1)HexNAc(1). (d) MS/MS spectra of a glycopeptide with Hex(2)HexNAc(2).

References

    1. Gahmberg CG & Tolvanen M Why mammalian cell surface proteins are glycoproteins. Trends in biochemical sciences 21, 308–311 (1996). - PubMed
    1. Jang JH & Hanash S Profiling of the cell surface proteome. Proteomics 3, 1947–1954, doi:10.1002/pmic.200300563 (2003). - DOI - PubMed
    1. Kovtun YV & Goldmacher VS Cell killing by antibody-drug conjugates. Cancer letters 255, 232–240, doi:10.1016/j.canlet.2007.04.010 (2007). - DOI - PubMed
    1. Selvaraj P et al. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 326, 400–403, doi:10.1038/326400a0 (1987). - DOI - PubMed
    1. Orentas RJ et al. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Frontiers in oncology 2, 194, doi:10.3389/fonc.2012.00194 (2012). - DOI - PMC - PubMed

Publication types